#IMUX

Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update Immunic (Nasdaq: IMUX) reported year-end 2025 results and a corporate update. Key developments include a completed oversubscribed private placement providing $200 million upfront (up to $400 million total), top-line Phase 3 ENSURE RMS data expected by year-end 2026, and plans for an NDA submission in mid-2027 with a targeted approval in 2028.The company disclosed a net loss of $97.2 million for 2025, R&D expense of $82.0 million, and cash & equivalents of $15.5 million as of Dec 31, 2025. Combined with ~$187.0 million net proceeds from the February 2026 financing, management expects funding into late 2027. Immunic plans a Phase 3 PPMS program and commercial buildout pending trial outcomes.

2 weeks ago

#IMUX Immunic, Inc. Reports Year-End 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/IMUX/immunic-inc-re...

0 0 0 0

@prismmarketview.bsky.social

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CRSR, #PATH, #IMUX, #HL, #CPRI

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Market Wire News

@marketwirenews.com

1 month ago

Breaking News: ( NASDAQ: #IMUX ) Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push

0 0 0 0

Market Wire News

@marketwirenews.com

1 month ago

News; ( NASDAQ: #IMUX ) Immunic Secures $400 Million Financing to Propel Multiple Sclerosis Programs and Commercial Transition

0 0 0 0

Market Wire News

@marketwirenews.com

1 month ago

BREAKING NEWS: ( NASDAQ: #IMUX ) Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company

0 0 0 0

PRISM MarketView

2 months ago

#ImmunicInc Advances Vidofludimus Calcium in MS with Key Milestones Achieved in 2025
#IMUX
prismmarketview.com/immunic-adva...

0 0 0 0

Immunic Highlights 2025 Accomplishments and Upcoming Milestones –Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026–. –U.S. Patent Allowed for Dose Strengths of Vidofludimus Calcium in Progressive Multiple Sclerosis, Strengthening Intellectual Property Protection Into 2041–. NEW YORK, Jan. 7, 2026/ PRNewswire/-- Immunic, Inc., a...

2 months ago

#IMUX Immunic Highlights 2025 Accomplishments and Upcoming Milestones

www.stocktitan.net/news/IMUX/immunic-highli...

0 0 0 0

Immunic's Participation in Evercore ISI Healthcare Conference to Share Insights on Innovative Therapies Immunic, Inc. will showcase its innovative therapies at the 8th Annual Evercore ISI Healthcare Conference on December 4, 2025. Tune in for updates!

3 months ago

Immunic's Participation in Evercore ISI Healthcare Conference to Share Insights on Innovative Therapies #USA #Immunic #Vidofludimus #IMUX #Coral_Gables,_FL

0 0 0 0

Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update –Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41 st Congress of ECTRIMS–. –Phase 2 CALLIPER Data Demonstrated Statistically Significant 24- Week Confirmed Disability Improvement in Progressive Multiple Sclerosis, With Consistent Signals for Slowing Disability Progression Across Subgroups...

4 months ago

#IMUX Immunic, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/IMUX/immunic-inc-re...

0 0 0 0

Immunic's Upcoming Participation in Key Investor Conferences This November Immunic, Inc. will engage in vital industry conferences this November, discussing advancements in its innovative therapies for autoimmune diseases.

4 months ago

Immunic's Upcoming Participation in Key Investor Conferences This November #USA #New_York #Immunic #IMUX #therapies

0 0 0 0

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis Immunic (NASDAQ:IMUX) presented key data for vidofludimus calcium in multiple sclerosis at the 41st ECTRIMS Congress. The phase 2 CALLIPER trial demonstrated statistically significant results in progressive multiple sclerosis, showing over two-fold probability of 24-week confirmed disability improvement versus placebo.The drug reduced the risk of 24-week confirmed disability worsening by 23.8% versus placebo in the overall population and by 33.7% in patients without gadolinium-enhancing lesions. Long-term data from the Phase 2 EMPhASIS trial in relapsing-remitting MS showed 92.3% of patients remained free of 12-week confirmed disability worsening at week 144, with favorable safety profiles.

5 months ago

#IMUX Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis

www.stocktitan.net/news/IMUX/immunic-presen...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Trade Alerts, Thursday September 11, 2025 – Crystal Equity Research

Small-cap stocks registering bullish MACD crossover signals, Thu Sept 11th - #VERO #SANA #RELL #AZTA #BWEN #CMMB #DERM #FLL #IMUX #LVO #MBIO #UDMY #TRUG #PDY #NVTS #YRD #UTL #LBRT - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Immunic (IMUX) Q2 Loss Widens 25% | The Motley Fool

#IMUX #d79e7c04-129e-4608-8837-44b439863fa0 #data-news

Origin | Interest | Match

0 0 0 0

Clinical Trial Success: New MS Drug Reduces Disease Progression by 24%, Immunic Secures $70M Funding Breakthrough MS treatment shows strong efficacy in reducing disability progression. Phase 3 trials fully enrolled, $70.1M raised to advance development. See complete results.

7 months ago

#IMUX Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/IMUX/immunic-inc-re...

0 0 0 0

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Immunic (NASDAQ:IMUX) has reported promising long-term data from the Phase 2 EMPhASIS trial's open-label extension (OLE) studying vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) patients. At Week 144, the trial demonstrated remarkable results with 92.3% of patients remaining free of 12-week confirmed disability worsening (CDW) and 92.7% free of 24-week CDW.The study, representing approximately 952 treatment years, showed that of 29 CDW events confirmed at 12 weeks, 44.8% were associated with relapse-associated worsening, while only 13.8% were linked to progression independent of relapse activity. The drug maintained a favorable safety profile with low discontinuation rates and no new safety signals emerging during treatment durations up to 5.5 years.

8 months ago

#IMUX Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

www.stocktitan.net/news/IMUX/immunic-report...

0 0 0 0

Immunic, Inc. Successfully Raises $65 Million in Oversubscribed Public Offering Immunic, Inc. has announced the pricing of a highly oversubscribed public offering, attracting $65 million to advance their clinical pipeline.

9 months ago

Immunic, Inc. Successfully Raises $65 Million in Oversubscribed Public Offering #United_States #New_York #Inc. #biotechnology #Immunic #IMUX

0 0 0 0

Immunic Secures Massive $195M Potential Funding: Oversubscribed Offering Signals Strong Investor Confidence Biotech firm raises $65M through warrant offering with potential for additional $130M. Funding targets clinical pipeline of oral therapies for inflammatory diseases. See details.

9 months ago

#IMUX Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering

www.stocktitan.net/news/IMUX/immunic-inc-an...

0 0 0 0

Immunic, Inc. Announces Proposed Public Offering Immunic (NASDAQ: IMUX), a biotech company focused on developing oral therapies for chronic inflammatory and autoimmune diseases, has announced a new public offering. The offering includes pre-funded warrants to purchase common stock, along with two series of warrants: Series A warrants expiring December 31, 2025, and Series B warrants expiring five years after issuance.Both Series A and B warrants will expire proportionally if the corresponding pre-funded warrant is exercised before September 30, 2025. Leerink Partners is serving as the sole bookrunner for the offering. The company plans to use the proceeds to fund clinical trials, operations, and general corporate purposes. The offering is being made through a shelf registration statement that became effective on May 31, 2024.

9 months ago

#IMUX Immunic, Inc. Announces Proposed Public Offering

www.stocktitan.net/news/IMUX/immunic-inc-an...

0 0 0 0

Breakthrough in Primary Progressive MS: Clinical Trial Shows 30% Reduced Disability Risk Phase 2 CALLIPER trial reveals promising neuroprotective effects in MS patients. Vidofludimus calcium shows strong efficacy in disability prevention. See full data.

10 months ago

#IMUX Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial

www.stocktitan.net/news/IMUX/immunic-announ...

0 2 0 0

10 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

Weekly Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IMUX 121% OTM
2. #AZUL 89% OTM
3. #FFIC 63% OTM
4. #CRVS 61% OTM
5. #PTON 57% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

10 months ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IMUX, #FFIC, #OMEX, #HIMS, #SMTC

#OptionFlow #OptionsTrading #Trading

1 0 0 0

10 months ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #IMUX 121% OTM
2. #FFIC 63% OTM
3. #CRVS 61% OTM
4. #MSTR 57% OTM
5. #SMCI 52% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Immunic, Inc. Completes $5.1 Million Equity Offering to Advance Pipeline Development Immunic, Inc. successfully closed a $5.1 million registered direct offering to enhance its clinical trials and further its drug development endeavors. This strategic financing will support its innovative therapies targeting chronic inflammatory diseases.

11 months ago

Immunic, Inc. Completes $5.1 Million Equity Offering to Advance Pipeline Development #United_States #New_York #Immunic #Aberdeen_Investments #IMUX

0 0 0 0

Immunic, Inc. Secures $5.1 Million in Direct Offering Led by Aberdeen Investments Immunic, Inc. has announced a registered direct offering of $5.1 million, to fund its clinical trials and operations, led by Aberdeen Investments.

11 months ago

Immunic, Inc. Secures $5.1 Million in Direct Offering Led by Aberdeen Investments #USA #New_York #Immunic #Aberdeen_Investments #IMUX

0 0 0 0

Immunic Lands $5.1M Institutional Backing: Aberdeen Investments Takes Major Stake Biotech firm raises $5.1M through direct offering at $0.90/share, strengthening pipeline development. Aberdeen Investments leads strategic funding round. Full details inside.

11 months ago

#IMUX Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments

www.stocktitan.net/news/IMUX/immunic-inc-an...

0 0 0 0

11 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IMUX, #MREO, #PSN, #SMG, #ASPN

#OptionFlow #OptionsTrading #Trading

0 0 0 0

11 months ago

🎯 Sweep Options Activity trade ideas! Institutions trading #options urgently with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#BABA, #APP, #INTC, #TEM, #IMUX

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Can Immunic's MS Drug Protect Neurons? New Data Reveals Promising Mechanism Ahead of Critical Trial Results Preclinical data shows neuroprotective properties via Nurr1 activation, reducing neuronal damage as company prepares for pivotal CALLIPER trial results in April.

1 year ago

#IMUX Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

www.stocktitan.net/news/IMUX/immunic-presen...

0 0 0 0